Heze Pharmaceutical Technology

Heze Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule drugs for endocrine-related diseases and oncology. The company focuses on targeting nuclear receptors, including estrogen and androgen receptors, to treat conditions such as breast cancer, prostate cancer, and endometriosis. Their lead programs include HZ-G131, a selective estrogen receptor degrader (SERD) for breast cancer, and HZ-A434 for prostate cancer. Heze Pharma leverages its expertise in medicinal chemistry to develop next-generation therapies with improved efficacy and safety profiles compared to existing standards of care.